819 results
Page 8 of 41
6-K
EX-99.4
gr0 yk52h5r
24 Feb 22
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
5:14pm
6-K
EX-99.1
0auqzgts hn
24 Feb 22
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
5:14pm
6-K
EX-99.2
x8eu592dz41185
24 Feb 22
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
5:14pm
6-K
EX-99.3
x07p3r3n8 57c
24 Feb 22
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
5:14pm
6-K
EX-99.1
lgjpho
14 Feb 22
FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease
2:07pm
6-K
EX-99.3
odv69v4 hufjxvkzt4j
14 Feb 22
FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease
2:07pm
6-K
EX-99.2
59b93 2f4
14 Feb 22
FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease
2:07pm
6-K
EX-99.1
es33mf
4 Feb 22
CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
1:29pm
6-K
EX-99.2
txdprfi nme9t8qpz9
4 Feb 22
CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
1:29pm
6-K
EX-99.1
qfaz8qlfiv4g05j uq
4 Feb 22
Strong 2021 sales and business EPS(1) growth enabling increased investment in R&D
9:56am
6-K
EX-99.1
5l1 du2tr
24 Jan 22
Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis
1:41pm
6-K
EX-99.1
nc0aslhnddoi9
12 Jan 22
Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines
1:47pm
6-K
EX-99.1
9r55h5f2y0ux8a
21 Dec 21
Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of Sanofi
1:28pm
6-K
EX-99.2
vmhgqw7t1t 4gtxxrw
21 Dec 21
Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of Sanofi
1:28pm
6-K
EX-99.3
yxbs5f0ad vsr
15 Dec 21
Current report (foreign)
2:50pm
6-K
EX-99.1
ye8b7c
15 Dec 21
Current report (foreign)
2:50pm
6-K
EX-99.4
tifdz8d802qj62 8jh
15 Dec 21
Current report (foreign)
2:50pm
6-K
EX-99.2
km4 wq0bl6jtcyo
15 Dec 21
Current report (foreign)
2:50pm
6-K
EX-99.2
wb4ukar1w3 40sw
6 Dec 21
Current report (foreign)
2:45pm